-
Mashup Score: 77Genentech: Press Releases | Sunday, Apr 14, 2024 - 9 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 26Genentech: Press Releases | Sunday, Feb 25, 2024 - 11 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: @NEJM publishes Phase III data demonstrating our medicine significantly reduced allergic reactions across multiple foods in people with #FoodAllergies. Learn more: https://t.co/JULZ6saQZ5
-
-
Mashup Score: 69Genentech: Press Releases | Friday, Feb 16, 2024 - 11 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: The @US_FDA approved our treatment as the first and only medicine for children and adults with one or more #FoodAllergies. Learn more: https://t.co/pzfZMuF3vd
-
-
Mashup Score: 14Genentech: Press Releases | Tuesday, Dec 19, 2023 - 1 year(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: The @US_FDA granted Priority Review to our medicine in children and adults with #FoodAllergy based on positive interim results from a first-of-its-kind Phase III @NIH and @NIAIDNews study. Read more here: https://t.co/PXrdYWcSWJ
-
-
Mashup Score: 6Genentech: Press Releases | Sunday, Dec 10, 2023 - 1 year(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: We’re presenting new data at #ASH23 that demonstrate continued benefit of our T-cell engaging bispecific antibodies for people with #lymphoma. Learn more: https://t.co/cGriKYRBLn
-
-
Mashup Score: 5Genentech: Press Releases | Saturday, Dec 9, 2023 - 1 year(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: We presented new data from a Phase III study of our medicine in infants with severe #hemophilia A at #ASH2023. Learn more: https://t.co/mpnfUKCsek
-
-
Mashup Score: 5Genentech: Press Releases | Friday, Dec 8, 2023 - 1 year(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: We’re presenting new pivotal data at #SABCS23 demonstrating the significant benefit of our investigational combination therapy on disease progression in certain types of advanced HR+/HER2- #breastcancer. Learn more: https://t.co/ixE3Mxyjy8
-
-
Mashup Score: 7Genentech: Press Releases | Friday, Dec 8, 2023 - 1 year(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: Long-term data at #SABCS23 shows significant overall survival benefit in people with HER2-positive early-stage #breastcancer. Read more about the results here: https://t.co/wFfYnNFxkx
-
-
Mashup Score: 12Genentech: Press Releases | Monday, Dec 4, 2023 - 1 year(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
ICYMI: We announced Phase III data that showed our investigational combination therapy for certain types of advanced #breastcancer met its primary endpoint of progression-free survival. Read more: https://t.co/WwLT4aAYew
-
-
Mashup Score: 21Genentech: Press Releases | Monday, Dec 4, 2023 - 1 year(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: Primary endpoint was met in a Genentech Phase III trial for people with certain types of advanced #breastcancer. https://t.co/PYG8FEWQca
-
#Breaking: Today we announced our CD20xCD3 bispecific antibody in combination with chemotherapy met its primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell #lymphoma, or #DLBCL. Learn more: https://t.co/IFU1bSUbev